Vident Advisory’s Biogen BIIB Stock Holding History

Vident Advisory’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$935K	Buy	5,101 +896	+21%	+$165K	0.01%	909
2025 Q4	$740K	Sell	4,205 -792	-16%	-$129K	0.01%	949
2025 Q3	$700K	Sell	4,997 -67	-1%	-$9.06K	0.01%	1009
2025 Q2	$636K	Sell	5,064 -1,766	-26%	-$220K	0.01%	923
2025 Q1	$935K	Buy	6,830 +5,444	+393%	+$778K	0.01%	753
2024 Q4	$212K	Buy	1,386 +166	+14%	+$28K	﹤0.01%	1327
2024 Q3	$237K	Sell	1,220 -504	-29%	-$105K	0.01%	1223
2024 Q2	$400K	Sell	1,724 -668	-28%	-$145K	0.01%	1010
2024 Q1	$516K	Sell	2,392 -6,642	-74%	-$1.56M	0.01%	812
2023 Q4	$2.34M	Buy	9,034 +2,969	+49%	+$729K	0.06%	338
2023 Q3	$1.56M	Buy	+6,065	New	+$1.62M	0.05%	378

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vident Advisory's BIIB Position: Q1 2026 in Review

Vident Advisory increased its Biogen (BIIB) stake by 21% in Q1 2026, buying an estimated $165K and bringing the position to 5,101 shares worth $935K. The position accounts for 0.01% of the portfolio, ranked #909.

Vident Advisory first reported a position in BIIB in Q3 2023 and has held it in 11 quarters since. The position peaked at $2.34M in Q4 2023. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Vident Advisory held 5,101 shares of Biogen worth $935K as of Q1 2026.
Vident Advisory bought 896 Biogen shares in Q1 2026, an estimated $165K.
Biogen made up 0.01% of Vident Advisory's portfolio in Q1 2026, its #909 holding.
Vident Advisory first reported a position in Biogen in Q3 2023 and has held it in 11 quarters since.
Vident Advisory's Biogen position peaked at $2.34M in Q4 2023.
1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.